Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.
Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results